ZA200201969B - Oral recombinant Lactobacilli vaccines. - Google Patents
Oral recombinant Lactobacilli vaccines. Download PDFInfo
- Publication number
- ZA200201969B ZA200201969B ZA200201969A ZA200201969A ZA200201969B ZA 200201969 B ZA200201969 B ZA 200201969B ZA 200201969 A ZA200201969 A ZA 200201969A ZA 200201969 A ZA200201969 A ZA 200201969A ZA 200201969 B ZA200201969 B ZA 200201969B
- Authority
- ZA
- South Africa
- Prior art keywords
- vaccine
- plantarum
- antigen
- lactobacillus
- bacterium
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 111
- 241000186660 Lactobacillus Species 0.000 title claims description 63
- 239000000427 antigen Substances 0.000 claims description 156
- 108091007433 antigens Proteins 0.000 claims description 154
- 102000036639 antigens Human genes 0.000 claims description 154
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 116
- 210000004027 cell Anatomy 0.000 claims description 83
- 241000894006 Bacteria Species 0.000 claims description 71
- 230000001580 bacterial effect Effects 0.000 claims description 66
- 230000014509 gene expression Effects 0.000 claims description 56
- 230000028993 immune response Effects 0.000 claims description 55
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 38
- 241000282414 Homo sapiens Species 0.000 claims description 37
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 35
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 35
- 230000004044 response Effects 0.000 claims description 32
- 241001465754 Metazoa Species 0.000 claims description 31
- 229940039696 lactobacillus Drugs 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 21
- 241000588724 Escherichia coli Species 0.000 claims description 20
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 19
- 239000004310 lactic acid Substances 0.000 claims description 19
- 235000014655 lactic acid Nutrition 0.000 claims description 19
- 229940126578 oral vaccine Drugs 0.000 claims description 19
- 239000013604 expression vector Substances 0.000 claims description 18
- 230000005847 immunogenicity Effects 0.000 claims description 18
- 241000282412 Homo Species 0.000 claims description 15
- 210000004877 mucosa Anatomy 0.000 claims description 15
- 230000003834 intracellular effect Effects 0.000 claims description 13
- 230000001681 protective effect Effects 0.000 claims description 13
- 241000894007 species Species 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 230000001717 pathogenic effect Effects 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 244000052769 pathogen Species 0.000 claims description 10
- 206010043376 Tetanus Diseases 0.000 claims description 9
- 230000002163 immunogen Effects 0.000 claims description 8
- 241000212468 Lactobacillus plantarum 80 Species 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 244000000010 microbial pathogen Species 0.000 claims description 7
- 239000013566 allergen Substances 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 4
- 241000702670 Rotavirus Species 0.000 claims description 4
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 4
- 241000607626 Vibrio cholerae Species 0.000 claims description 4
- 244000045947 parasite Species 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 229940118376 tetanus toxin Drugs 0.000 claims description 4
- 241000193468 Clostridium perfringens Species 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- 239000002158 endotoxin Substances 0.000 claims description 3
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 3
- 241000186046 Actinomyces Species 0.000 claims description 2
- 241000712891 Arenavirus Species 0.000 claims description 2
- 241000193738 Bacillus anthracis Species 0.000 claims description 2
- 241000588832 Bordetella pertussis Species 0.000 claims description 2
- 241000589969 Borreliella burgdorferi Species 0.000 claims description 2
- 241001136175 Burkholderia pseudomallei Species 0.000 claims description 2
- 241000589876 Campylobacter Species 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims description 2
- 241000498849 Chlamydiales Species 0.000 claims description 2
- 241000193403 Clostridium Species 0.000 claims description 2
- 241000193155 Clostridium botulinum Species 0.000 claims description 2
- 241001445332 Coxiella <snail> Species 0.000 claims description 2
- 201000007336 Cryptococcosis Diseases 0.000 claims description 2
- 241000221204 Cryptococcus neoformans Species 0.000 claims description 2
- 241000223935 Cryptosporidium Species 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 241000224432 Entamoeba histolytica Species 0.000 claims description 2
- 101710091045 Envelope protein Proteins 0.000 claims description 2
- 241000244009 Filarioidea Species 0.000 claims description 2
- 241000711950 Filoviridae Species 0.000 claims description 2
- 241000590002 Helicobacter pylori Species 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 241000222722 Leishmania <genus> Species 0.000 claims description 2
- 241000186779 Listeria monocytogenes Species 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 claims description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 claims description 2
- 241000186362 Mycobacterium leprae Species 0.000 claims description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 2
- 241000243985 Onchocerca volvulus Species 0.000 claims description 2
- 241000150452 Orthohantavirus Species 0.000 claims description 2
- 108010081690 Pertussis Toxin Proteins 0.000 claims description 2
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 claims description 2
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 claims description 2
- 208000000474 Poliomyelitis Diseases 0.000 claims description 2
- 101710188315 Protein X Proteins 0.000 claims description 2
- 241000125945 Protoparvovirus Species 0.000 claims description 2
- 241000711798 Rabies lyssavirus Species 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
- 241000710799 Rubella virus Species 0.000 claims description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 2
- 108010079723 Shiga Toxin Proteins 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 2
- 241000589886 Treponema Species 0.000 claims description 2
- 241000607479 Yersinia pestis Species 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940007078 entamoeba histolytica Drugs 0.000 claims description 2
- 230000000688 enterotoxigenic effect Effects 0.000 claims description 2
- 229940037467 helicobacter pylori Drugs 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 201000000317 pneumocystosis Diseases 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 230000000063 preceeding effect Effects 0.000 claims 6
- 241000224467 Giardia intestinalis Species 0.000 claims 1
- 208000005647 Mumps Diseases 0.000 claims 1
- 102100021696 Syncytin-1 Human genes 0.000 claims 1
- 229940085435 giardia lamblia Drugs 0.000 claims 1
- 208000010805 mumps infectious disease Diseases 0.000 claims 1
- 108010044241 tetanus toxin fragment C Proteins 0.000 description 63
- 241000699670 Mus sp. Species 0.000 description 39
- 244000199866 Lactobacillus casei Species 0.000 description 38
- 238000002649 immunization Methods 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 32
- 229960000814 tetanus toxoid Drugs 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 25
- 229940027941 immunoglobulin g Drugs 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 19
- 238000011740 C57BL/6 mouse Methods 0.000 description 18
- 210000000952 spleen Anatomy 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 235000013305 food Nutrition 0.000 description 14
- 210000000628 antibody-producing cell Anatomy 0.000 description 13
- 235000013958 Lactobacillus casei Nutrition 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 229940099472 immunoglobulin a Drugs 0.000 description 12
- 229940017800 lactobacillus casei Drugs 0.000 description 12
- 244000010815 Phlomis lychnitis Species 0.000 description 11
- 238000009472 formulation Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical group O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 230000002688 persistence Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 210000002421 cell wall Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000008105 immune reaction Effects 0.000 description 6
- 230000037452 priming Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 238000011725 BALB/c mouse Methods 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108010046334 Urease Proteins 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 239000004382 Amylase Substances 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- 241000252983 Caecum Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000002464 Galactosidases Human genes 0.000 description 2
- 108010093031 Galactosidases Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 241000186684 Lactobacillus pentosus Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000004460 silage Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 241000186713 Lactobacillus amylovorus Species 0.000 description 1
- 241000186712 Lactobacillus animalis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000186842 Lactobacillus coryniformis Species 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241001134654 Lactobacillus leichmannii Species 0.000 description 1
- 241000186871 Lactobacillus murinus Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000866650 Lactobacillus paraplantarum Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 229940124859 Rotavirus vaccine Drugs 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000194026 Streptococcus gordonii Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- -1 fractions Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930186900 holotoxin Natural products 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 231100001039 immunological change Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99203056A EP1084709A1 (en) | 1999-09-17 | 1999-09-17 | Oral recombinant lactobacilli vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200201969B true ZA200201969B (en) | 2003-08-27 |
Family
ID=8240652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200201969A ZA200201969B (en) | 1999-09-17 | 2002-03-08 | Oral recombinant Lactobacilli vaccines. |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP1084709A1 (zh) |
| JP (1) | JP2003509469A (zh) |
| CN (1) | CN1387442A (zh) |
| AP (1) | AP2002002445A0 (zh) |
| AU (1) | AU7433700A (zh) |
| CA (1) | CA2383433A1 (zh) |
| IL (1) | IL148713A0 (zh) |
| OA (1) | OA12023A (zh) |
| WO (1) | WO2001021200A1 (zh) |
| ZA (1) | ZA200201969B (zh) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7220418B1 (en) | 1999-07-05 | 2007-05-22 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Delivery of trefoil peptides |
| US7060687B2 (en) | 2001-02-07 | 2006-06-13 | Genmont Biotechnology Co. | Live vaccines for allergy treatment |
| JP4059648B2 (ja) * | 2001-08-28 | 2008-03-12 | 独立行政法人科学技術振興機構 | 経口用サイトカイン誘導剤 |
| GB0124580D0 (en) * | 2001-10-12 | 2001-12-05 | Univ Reading | New composition |
| EP1319410A1 (en) * | 2001-12-11 | 2003-06-18 | Société des Produits Nestlé S.A. | Use of micro-organisms for a directed delivery of substances to specific parts of the gut |
| US20040043003A1 (en) * | 2002-01-31 | 2004-03-04 | Wei Chen | Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions |
| CA2492685A1 (en) * | 2002-06-18 | 2003-12-24 | Universite Catholique De Louvain | Cell wall mutants for delivery of biologically active compounds |
| NZ544116A (en) * | 2003-05-22 | 2008-03-28 | Synbiotics Ab | A probiotic composition comprising at least two lactic acid bacterial strains which are able to colonise the gastrointestinal tracts in combination with having intestinal survival property, intestinal binding property, an infection protection property and a fiber fermenting property |
| EP1680508B1 (en) * | 2003-10-28 | 2011-03-30 | Friesland Brands B.V. | Site-specific intestinal delivery and/or production of biologically active substances |
| US8821893B2 (en) * | 2004-07-02 | 2014-09-02 | Bio Peptides, Corp. | Oral vaccine for Borrelia |
| EP1723965A1 (en) * | 2005-05-18 | 2006-11-22 | Stallergenes Sa | Compositions for antigen-specific induction of immuno-tolerance via oral immunization |
| JPWO2006126682A1 (ja) * | 2005-05-27 | 2008-12-25 | 財団法人化学及血清療法研究所 | アルツハイマー病の予防・治療用ワクチン |
| PL1951273T3 (pl) * | 2005-10-06 | 2014-07-31 | Probi Ab | Zastosowanie lactobacillus do leczenia chorób autoimmunologicznych |
| WO2007106073A2 (en) | 2006-03-02 | 2007-09-20 | University Of Massachusetts | Modified pathogens for use as vaccines |
| JP5791009B2 (ja) * | 2008-12-22 | 2015-10-07 | アサヒグループホールディングス株式会社 | 乳酸菌およびそれらを用いた飲食物又は化粧品 |
| DK2694101T3 (en) | 2011-04-06 | 2017-01-09 | Biovaxim Ltd | Pharmaceutical compositions for the prevention and / or treatment of HIV disease in humans |
| CN103732248B (zh) * | 2011-04-06 | 2018-08-28 | 拜欧瓦克西姆有限公司 | 用于预防和/或治疗人中的hiv疾病的药物组合物 |
| CN102580118B (zh) * | 2012-02-24 | 2014-03-12 | 重庆大学 | 志贺样毒素Stx1B口服疫苗的制备方法及其产品 |
| WO2014047625A1 (en) * | 2012-09-24 | 2014-03-27 | Montana State University | Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use |
| US10314916B2 (en) | 2013-06-11 | 2019-06-11 | House Wellness Foods Corporation | Carrier for delivery of substance to phagocytes |
| AU2019245479A1 (en) * | 2018-03-31 | 2020-10-29 | Pebble Labs Usa Inc. | Systems, methods and composition of using RNase III mutants to produce sRNA to control host pathogen infection |
| AU2021380725A1 (en) * | 2020-11-10 | 2023-07-06 | Elanco Us Inc. | Immunogenic probiotic compositions and methods of use including in vaccination |
| GB202019767D0 (en) | 2020-12-15 | 2021-01-27 | Chain Biotechnology Ltd | Compostitions and methods |
| CN113308396B (zh) * | 2021-05-18 | 2023-03-21 | 上海市公共卫生临床中心 | 一种植物乳杆菌及在制备新冠疫苗免疫增强剂中的应用 |
| CN113304254A (zh) * | 2021-06-07 | 2021-08-27 | 吉林大学 | 一种微小隐孢子虫Cp15重组侵入型乳酸菌活载体疫苗 |
| CN114561313B (zh) * | 2021-08-26 | 2022-09-13 | 佛山市孛特碧欧微生物科技有限公司 | 格氏乳杆菌及其应用 |
| GB202209115D0 (en) | 2022-06-21 | 2022-08-10 | Chain Biotechnology Ltd | Compositions and methods |
| DE102022119024A1 (de) * | 2022-07-28 | 2024-02-08 | INM - Leibniz-Institut für Neue Materialien gemeinnützige Gesellschaft mit beschränkter Haftung | Neuartige genetische Werkzeuge |
| CN117586935B (zh) * | 2023-12-01 | 2024-05-10 | 华中农业大学 | 用于产肠毒素大肠杆菌k99菌毛型的乳酸乳球菌载体口服疫苗及应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8700890A (nl) * | 1987-04-15 | 1988-11-01 | Tno | Transformatie van lactobacillus, daarbij bruikbare recombinante plasmiden, getransformeerde lactobacillus species en gebruik daarvan. |
| GB9718616D0 (en) * | 1997-09-02 | 1997-11-05 | Queen Mary & Westfield College | Oral vaccine |
-
1999
- 1999-09-17 EP EP99203056A patent/EP1084709A1/en not_active Withdrawn
-
2000
- 2000-09-18 IL IL14871300A patent/IL148713A0/xx unknown
- 2000-09-18 CA CA002383433A patent/CA2383433A1/en not_active Abandoned
- 2000-09-18 CN CN00815334A patent/CN1387442A/zh active Pending
- 2000-09-18 AU AU74337/00A patent/AU7433700A/en not_active Abandoned
- 2000-09-18 AP APAP/P/2002/002445A patent/AP2002002445A0/en unknown
- 2000-09-18 EP EP00962689A patent/EP1212083A1/en not_active Withdrawn
- 2000-09-18 WO PCT/GB2000/003575 patent/WO2001021200A1/en not_active Application Discontinuation
- 2000-09-18 OA OA1200200076A patent/OA12023A/en unknown
- 2000-09-18 JP JP2001524624A patent/JP2003509469A/ja active Pending
-
2002
- 2002-03-08 ZA ZA200201969A patent/ZA200201969B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1084709A9 (en) | 2001-05-16 |
| IL148713A0 (en) | 2002-09-12 |
| EP1084709A1 (en) | 2001-03-21 |
| JP2003509469A (ja) | 2003-03-11 |
| AP2002002445A0 (en) | 2002-03-31 |
| EP1212083A1 (en) | 2002-06-12 |
| OA12023A (en) | 2006-04-19 |
| CA2383433A1 (en) | 2001-03-29 |
| WO2001021200A1 (en) | 2001-03-29 |
| CN1387442A (zh) | 2002-12-25 |
| AU7433700A (en) | 2001-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200201969B (en) | Oral recombinant Lactobacilli vaccines. | |
| Kajikawa et al. | Intragastric immunization with recombinant Lactobacillus casei expressing flagellar antigen confers antibody-independent protective immunity against Salmonella enterica serovar Enteritidis | |
| Pouwels et al. | The potential of Lactobacillus as a carrier for oral immunization: development and preliminary characterization of vector systems for targeted delivery of antigens | |
| AU767143B2 (en) | Lactobacilli harboring aggregation and mucin binding genes as vaccine delivery vehicles | |
| US9011870B2 (en) | Bifunctional protein anchors | |
| Mohamadzadeh et al. | Targeting mucosal dendritic cells with microbial antigens from probiotic lactic acid bacteria | |
| Wen et al. | Immunization with recombinant Lactobacillus casei strains producing K99, K88 fimbrial protein protects mice against enterotoxigenic Escherichia coli | |
| CN108779482B (zh) | 工程化肠道共生细菌在其外膜囊泡(omv)中表达异源蛋白质以递送至胃肠道 | |
| Kajikawa et al. | Innate and acquired immune responses induced by recombinant Lactobacillus casei displaying flagellin-fusion antigen on the cell-surface | |
| WO2003063785A2 (en) | Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa | |
| Yang et al. | Alleviation of enterotoxigenic Escherichia coli challenge by recombinant Lactobacillus plantarum expressing a FaeG-and DC-targeting peptide fusion protein | |
| JP2005528085A (ja) | 修飾された細菌表層タンパク質 | |
| CN117202927A (zh) | 组合物和方法 | |
| Havenith et al. | Gut-associated lactobacilli for oral immunisation | |
| US20040009937A1 (en) | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system | |
| US20050075298A1 (en) | Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa | |
| Manohar et al. | Enhancement of live vaccines by co-delivery of immune modulating proteins | |
| Mohamadzadeh | Induction of protective immunity against microbial challenge by targeting antigens expressed by probiotic bacteria to mucosal dendritic cells | |
| AU2003249855B2 (en) | Cell wall mutants for delivery of biologically active compounds | |
| WO2003074681A1 (en) | Recombinant spores | |
| WO2003063786A2 (en) | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system | |
| Boersma et al. | Probiotic bacteria as live oral vaccines Lactobacillus as the versatile delivery vehicle | |
| WO2023247936A1 (en) | Compositions and methods | |
| WO1999011284A1 (en) | Oral vaccine | |
| Singh et al. | Future Application of Probiotics: A Boon from Dairy Biology |